Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (AU:RMD)
ASX:RMD
Want to see AU:RMD full AI Analyst Report?
RMD Stock Chart & Stats
AU$31.52
AU$0.22(0.59%)
At close: 4:00 PM EST
AU$31.52
AU$0.22(0.59%)
Day’s Range― - ―
52-Week RangeAU$25.50 - AU$45.25
Previous CloseN/A
Volume1.29M
Average Volume (3M)1.08M
Market Cap
AU$39.66B
Enterprise ValueAU$26.83B
Total Cash (Recent Filing)AU$1.67B
Total Debt (Recent Filing)AU$847.66M
Price to Earnings (P/E)18.5
Beta0.70
Next Earnings
Jul 30, 2026EPS Estimate
0.4Next Dividend Ex-DateN/A
Dividend Yield0.95%
Share Statistics
EPS (TTM)3.18
Shares Outstanding1,450,563,800
10 Day Avg. Volume805,465
30 Day Avg. Volume1,076,544
Financial Highlights & Ratios
PEG Ratio0.75
Price to Book (P/B)6.36
Price to Sales (P/S)7.38
P/FCF Ratio23.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$42.70Price Target Upside35.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)1.11
Revenue Forecast (FY)AU$5.65B
Bulls Say, Bears Say
Bulls Say
Market OpportunitiesThere is no clarity on Philips’ return to the US market, which may benefit RMD in the short term.
Promotional ActivitiesRMD expects its sponsors to ramp up promotional activity in 2H CY25, which could positively impact the business.
Valuation And GrowthUpgrade to Buy on reasonable valuation, strong EPS growth, FCF, and no debt by FY end.
Bears Say
Healthcare CapacityHealthcare systems’ capacity constraints will likely keep a lid on new patients growth.
Market ReactionRMD’s share price has historically reacted negatively to news flow on GLP-1s.
Product PerformanceThe growth in RMD US app downloads is tracking below the US Devices sales growth consensus.
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh News
RMD FAQ
What was Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh’s price range in the past 12 months?
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh lowest share price was AU$25.50 and its highest was AU$45.25 in the past 12 months.
What is Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh’s market cap?
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh’s market cap is AU$39.66B.
When is Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh’s upcoming earnings report date?
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh’s upcoming earnings report date is Jul 30, 2026 which is in 48 days.
How were Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh’s earnings last quarter?
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh released its earnings results on Apr 30, 2026. The company reported AU$0.395 earnings per share for the quarter, beating the consensus estimate of AU$0.386 by AU$0.008.
Is Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh overvalued?
According to Wall Street analysts Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh’s price is currently Undervalued.
Does Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh pay dividends?
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh pays a Quarterly dividend of AU$0.085 which represents an annual dividend yield of 0.95%. See more information on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh dividends here
What is Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh’s EPS estimate?
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh’s EPS estimate is 0.4.
How many shares outstanding does Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh have?
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh has 1,450,563,800 shares outstanding.
What happened to Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh’s price movement after its last earnings report?
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh reported an EPS of AU$0.395 in its last earnings report, beating expectations of AU$0.386. Following the earnings report the stock price went down -3.523%.
Which hedge fund is a major shareholder of Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh?
Currently, no hedge funds are holding shares in AU:RMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
AU$42.70 (35.46% Upside)
AU$42.70 (35.46% Upside)
Blogger Sentiment
Bullish
AU:RMD Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
16.26%
12-Months-Change
Fundamentals
Return on Equity
24.41%
Trailing 12-Months
Asset Growth
5.62%
Trailing 12-Months
Company Description
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
ResMed Inc. designs, manufactures, and markets innovative medical devices and sophisticated cloud-based software platforms for the global healthcare industry, operating through its Sleep and Respiratory Care, and Software as a Service divisions. Within its Sleep and Respiratory Care segment, the company offers a comprehensive range of solutions for various respiratory disorders. These include cutting-edge ventilation devices, diagnostic tools, diverse mask systems suitable for hospital and home environments, headgear, accessories, and specialized dental devices. These hardware offerings are integrated with cloud-based informatics solutions designed to optimize patient management and improve clinical results. Prominent software applications in this area feature AirView, a cloud platform for remote patient monitoring and device setting modifications; myAir, a personalized therapy management tool for sleep apnea sufferers, providing education, support, and troubleshooting to enhance engagement and adherence; and U-Sleep, a compliance monitoring system that streamlines sleep programs for home medical equipment (HME) providers. The company also offers connectivity modules and Propeller solutions. The Software as a Service division specializes in out-of-hospital care solutions. Brightree provides business management software and services to providers in the home medical equipment, pharmacy, home infusion, orthotics, and prosthetics sectors. MatrixCare delivers care management and ancillary solutions to senior living communities, skilled nursing facilities, life plan communities, home health, home care, and hospice organizations, including related accountable care organizations. Furthermore, HEALTHCAREfirst supplies electronic health record (EHR) systems, software, billing and coding services, and analytics tailored for home health and hospice agencies. ResMed distributes its extensive product line to sleep clinics, home healthcare dealers, and hospitals in approximately 140 countries, utilizing both a direct sales force and a network of distributors. The company was founded in 1989 and is based in San Diego, California.
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) Earnings & Revenues
RMD Revenue Breakdown
88.21% Sleep and Respiratory Care
11.79% Software as a Service
RMD Stock 12 Month Forecast
Average Price Target
AU$42.70
▲(35.46% Upside)
Technical Analysis
Compumedics Limited
―
Somnomed Limited
―
Paragon Care Limited
―
Alcidion Group Limited
―
4DMedical Ltd
―
Options Prices
Currently, No data available
---